- Home
- YQ vs MRKR Comparison
YQ vs MRKR Comparison
Compare YQ & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- MRKR
- Stock Information
- Founded
- YQ 2012
- MRKR N/A
- Country
- YQ China
- MRKR United States
- Employees
- YQ N/A
- MRKR N/A
- Industry
- YQ Other Consumer Services
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- MRKR Health Care
- Exchange
- YQ Nasdaq
- MRKR Nasdaq
- Market Cap
- YQ 15.2M
- MRKR 13.4M
- IPO Year
- YQ 2020
- MRKR N/A
- Fundamental
- Price
- YQ $2.01
- MRKR $1.52
- Analyst Decision
- YQ
- MRKR Strong Buy
- Analyst Count
- YQ 0
- MRKR 3
- Target Price
- YQ N/A
- MRKR $13.17
- AVG Volume (30 Days)
- YQ 59.2K
- MRKR 181.1K
- Earning Date
- YQ 06-10-2025
- MRKR 05-15-2025
- Dividend Yield
- YQ N/A
- MRKR N/A
- EPS Growth
- YQ N/A
- MRKR N/A
- EPS
- YQ N/A
- MRKR N/A
- Revenue
- YQ $25,922,648.00
- MRKR $5,696,123.00
- Revenue This Year
- YQ N/A
- MRKR N/A
- Revenue Next Year
- YQ N/A
- MRKR $11.28
- P/E Ratio
- YQ N/A
- MRKR N/A
- Revenue Growth
- YQ 10.68
- MRKR 71.53
- 52 Week Low
- YQ $1.26
- MRKR $0.95
- 52 Week High
- YQ $3.19
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- YQ 51.38
- MRKR 64.76
- Support Level
- YQ $1.95
- MRKR $1.12
- Resistance Level
- YQ $2.35
- MRKR $1.82
- Average True Range (ATR)
- YQ 0.24
- MRKR 0.15
- MACD
- YQ -0.01
- MRKR 0.05
- Stochastic Oscillator
- YQ 24.62
- MRKR 60.00
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.